Skip Navigation


NDT Advance Access originally published online on January 18, 2007
Nephrology Dialysis Transplantation 2007 22(4):981-988; doi:10.1093/ndt/gfl814
This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
22/4/981    most recent
gfl814v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in NDT
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Wiecek, A.
Right arrow Articles by Chudek, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wiecek, A.
Right arrow Articles by Chudek, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Adiponectin—an adipokine with unique metabolic properties

Andrzej Wiecek, Marcin Adamczak and Jerzy Chudek

Department of Nephrology, Endocrinology and Metabolic Diseases, Medical University of Silesia, Katowice, Poland

Correspondence and offprint requests to: Prof. dr hab. med. Andrzej Wiecek, FRCP (Edin), Department of Nephrology, Endocrinology and Metabolic Diseases, Medical University of Silesian, Katowice, ul. Francuska 20/24, 40-027 Katowice, Poland. Email: awiecek{at}spskm.katowice.pl

Keywords: adipocytes; adipokines; adiponectin



   Introduction
Top
 Introduction
Adiponectin--a unique adipokine...
 Adiponectin in chronic kidney...
 Plasma adiponectin concentration...
 How to increase plasma...
 References
 
The epidemic of visceral obesity and its complications: insulin resistance, type 2 diabetes mellitus, obesity-related arterial hypertension, and obesity-related glomerulopathy is a challenging health problem for modern societies in the 21st century.

In the last decade, adipose tissue was recognized as an active endocrine organ that can affect the function of other organs and is an important source of several hormones: cytokines, chemokines, growth factors and complement proteins called ‘adipokines’ or ‘adipocytokines’ (for review see [1,2]). Many of them may influence the function of the cardiovascular system. An incomplete list of such adipokines is presented in Table 1.


View this table:
[in this window]
[in a new window]

  		Table 1. List of hormones, cytokines, chemokines, growth factors and complement proteins produced by the adipose tissue

 
The role of one very promising adipokine—adiponectin, in the pathogenesis of cardiovascular and renal diseases is discussed in this review.



   Adiponectin—a unique adipokine with anti-atherogenic, anti-inflammatory and insulin-sensitizing properties
Top
 Introduction
 Adiponectin--a unique adipokine...
Adiponectin in chronic kidney...
 Plasma adiponectin concentration...
 How to increase plasma...
 References
 
Adiponectin is a 30 kDa protein hormone secreted almost exclusively by adipocytes with anti-atherogenic, anti-inflammatory and insulin-sensitizing properties. Adiponectin gene expression is increased 100-fold during differentiation of human cultured preadipocytes [3]. Higher adiponectin gene expression and protein content was found in adipocytes localized in subcutaneous than in visceral adipose tissue [4]. Plasma concentration of adiponectin is relatively high (almost 0.01% of total plasma protein) [5]. Adiponectin is present as full-length molecules (almost all) or smaller globular C-terminal domain fragments (see [6,7] for review). Within the circulation, adiponectin forms a wide range of multimers: from trimers (low molecular weight, LMW), hexamers (medium molecular weight, MMW) to 12-mers or 18-mers (high molecular weight, HMW) [7] (Figure 1). Different forms of adiponectin, aforementioned, may potentially possess different physiological properties.


Figure 1
View larger version (23K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 1. Adiponectin is present as full-length molecules (almost all) or smaller globular C-terminal domain fragments. Within the circulation, adiponectin forms a wide range of multimers: from trimers (low molecular weight, LMW), hexamers (medium molecular weight, MMW) to 12-mers or 18-mers (high molecular weight, HMW). Different forms of adiponectin aforementioned, may potentially posses a different physiological properties.

 
In contrast to other adipokines (for example leptin), plasma concentration of adiponectin is lower in obese than in non-obese subjects [5]. The mechanisms leading to reduced plasma adiponectin concentration in obese subjects are not yet fully clarified. One possible mechanism comprises inhibition of adiponectin synthesis and secretion by tumour necrosis factor (TNF)-{alpha} [8,9], which is locally produced in increased amounts in visceral obesity, predominantly by macrophages infiltrating adipose tissue [10–12].

Lower adiponectinaemia was found in males than in females, smokers than non-smokers, and in patients with coronary artery disease, diabetes mellitus type 2 and essential hypertension than in healthy subjects [13–16]. Of interest, some of the common polymorphisms in the promoter region, exon and intron 2 and the rare mutations in exon 3 of the human adiponectin gene are associated with phenotypes related to obesity, insulin resistance and the risk of diabetes mellitus and coronary artery disease (for review see [17]).

Adiponectin receptors were found among others in the skeletal muscle (Adipo R1), liver (Adipo R2) and endothelial cells (Adipo R1) [18,19]. It has been shown that in obese subjects and patients with type 2 diabetes mellitus, besides lower plasma adiponectin concentration, adiponectin receptor expression is also reduced [20,21]. Therefore in such patients, significant reduction of adiponectin sensitivity might occur. Interestingly, this is a reversible phenomenon, i.e. in obese subjects after weight reduction, an increase of Adipo R1 receptor expression and of adiponectinaemia were observed [22].

Experimental studies showed that adiponectin prevents both atherogenesis and its acute thrombotic complications, through the number of different mechanisms (Table 2, Figure 2). Adiponectin inhibits formation of initial atherosclerotic lesions, i.e. monocyte attachment to vascular bed by decreasing expression of adhesion molecules (VCAM-1; ICAM-1, E-selectin) in endothelial cells, in response to inflammatory stimuli such as TNF-{alpha} [23]. Adiponectin also suppresses the production of proinflammatory cytokines, such as TNF-{alpha} by macrophages [8,9]. Adiponectin reduces accumulation of lipids in human monocyte-derived macrophages and inhibits transformation of macrophages into foam cells (through down-regulation of scavenger receptors) [24]. It also inhibits cell proliferation stimulated by oxidized low-density lipoprotein (LDL) and suppresses superoxide generation [25,26]. The hallmark of atherosclerosis is uncontrolled proliferation and migration of smooth muscle cells, which leads to thickening of the vascular wall. Adiponectin attenuates growth-factor induced proliferation of vascular smooth muscle cells, by inhibition of mitogen-activated protein kinase [27]. Moreover, it was shown that the oligomeric complexes of adiponectin can modulate the biological actions of growth factors, by binding with platelet-derived growth factor BB (PDGF-BB), basic fibroblast growth factor (FGF), and heparin-binding epidermal growth factor-like growth factor (HB EGF) [28]. In this way, adiponectin controls their bioavailability at a pre-receptor level and this effect might partially account for the anti-atherogenic action of adiponectin. It was also shown that adiponectin increases activity of endothelial nitric oxide (NO) synthase and as a consequence, enhances NO production by endothelial cells [19,29]. This is in line with the observations made by Ouchi et al. [30], who found that endothelium-dependent vasorelaxation is impaired in adiponectin knockout mice. Such disturbed vasorelaxation might be one of the mechanisms leading to hypertension and atherosclerosis in obesity. Finally, it was shown that adiponectin protects ApoE-deficient mice (a well-known animal model of atherosclerosis) from atherosclerosis [31,32].


View this table:
[in this window]
[in a new window]

  		Table 2. Proposed mechanisms of anti-atherogenic action of adiponectin

 

Figure 2
View larger version (26K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 2. Anti-atherogenic and of insulin-sensitizing actions of adiponectin.

 
Adiponectin prevents atherosclerotic plaque rupture by stabilization of plaque structure through increasing expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in infiltrating macrophages [33]. It may also protect against ischaemic-reperfusion myocardial injury, as the size of myocardial infarct is larger in adiponectin knockout mice than in wild-type mice after ischaemia-reperfusion injury [34]. Moreover, administration of adiponectin diminished infarct size in these mice [34]. In the long run, after myocardial injury adiponectin may regulate myocardial remodelling. It was shown that adiponectin knockout mice, after myocardial infarction, were characterized by exacerbated left ventricular dilatation and contractile dysfunction and reduced capillary density in the infarct border zone compared with wild-type mice [35]. Again, administration of adiponectin prevented such exacerbation of myocardial damage and dysfunction [35]. In this context, it is of interest that adiponectin stimulates angiogenesis in response to tissue ischaemia [36]. Shibata et al. [36] showed that angiogenic repair of ischaemic hind limbs was impaired in adiponectin knockout mice compared with wild-type mice, as evaluated by laser Doppler flow method and capillary density analyses. Adenovirus-mediated supplementation of adiponectin accelerated angiogenic repair both in adiponectin knockout mice and wild-type mice [36]. Finally, adiponectin promotes endothelial differentiation from peripheral blood CD14(+) monocytes, which may contribute to vascular healing and angiogenesis [37].

Low plasma adiponectin concentration may be also involved in pathogenesis of left ventricular hypertrophy. It was shown in adiponectin knockout mice that adiponectin deficiency leads to progressive cardiac remodelling in pressure overloaded condition [38,39]. Once again, adenovirus-mediated supplementation of adiponectin attenuated cardiac hypertrophy in this experimental condition [39].

Adiponectin was initially recognized as an inverse predictor of cardiovascular events and mortality in a cohort of haemodialysis patients [40] and later extended by prospective epidemiological studies into the general population [41], patients with diabetes mellitus type 2 [42] and patients with chest pain undergoing coronary angiography (with stable angina, troponin-negative unstable angina, or non-ST-segment elevation myocardial infarction) [43]. Moreover, patients with ischaemic heart disease and low plasma adiponectin concentration are characterized by more severe atherosclerosis in coronary arteries examined by angiography when compared with those with higher plasma values [44,45]. In the general population, the right common carotid artery intima media thickness were significantly higher in the male subjects with the lowest plasma adiponectin concentration quartile, when compared with the highest quartile [46].

Experimental studies showed that adiponectin improves insulin sensitivity through a number of different mechanisms (Table 3, Figure 2) (for review [47]). It was showed that adiponectin stimulates glucose utilization and fatty acid oxidation in skeletal muscles and in the liver [48]. Adiponectin facilities glucose uptake, through increase of glucose transporter 4 expression and its translocation [49,50]. It also suppresses gluconeogenesis in the liver [48]. Interestingly, in clinical studies plasma HMW adiponectin concentration showed a tighter relationship with glucose tolerance and insulin sensitivity than total plasma concentration of adiponectin [51]. Therefore, impaired multimerization of adiponectin seems also to participate in the pathogenesis of diabetes mellitus type 2 [52]. In non-human primates, it was shown that reduction of plasma adiponectin concentration occurs before the onset of obesity and insulin resistance, suggesting that hypoadiponectinaemia indeed plays an important role in the pathogenesis of such metabolic disturbances [53].


View this table:
[in this window]
[in a new window]

  		Table 3. Proposed mechanisms of insulin-sensitizing action of adiponectin

 
In an epidemiological study, it was shown that low plasma adiponectin concentration is an independent risk predictor for development of insulin resistance, impaired glucose metabolism (IGM) and type 2 diabetes [54,55]. Bayes et al. [56] also showed that low pre-transplant plasma adiponectin concentration is a risk factor for development of new-onset diabetes mellitus after kidney transplantation, one of the factors for shortened patient and graft survival.

The association between reduced foetal weight and consequences of metabolic syndrome in adult life such as dyslipidaemia, hypertension, diabetes mellitus type 2 and increased risk for cardiovascular events has been clearly documented. Recently, it was shown that young adults born with a small-for-gestational age (SGA) are characterized by significantly lower plasma adiponectin concentration in comparison with young adults born with an appropriate-for-gestational age [57]. This adverse effect of SGA on adiponectin secretion in adults provides an additional example of the deleterious metabolic consequences related to reduced fetal growth.



   Adiponectin in chronic kidney disease (CKD) patients
Top
 Introduction
 Adiponectin--a unique adipokine...
 Adiponectin in chronic kidney...
Plasma adiponectin concentration...
 How to increase plasma...
 References
 
An inverse relationship was found between plasma adiponectin concentrations and kidney function assessed by glomerular filtration rate (GFR) in apparently healthy individuals [58], patients with essential hypertension [59], renovascular hypertension [60], mild or moderate non-diabetic CKD [61], diabetes mellitus type 1 with nephropathy [62,63] and kidney transplant subjects [64]. In haemodialysis patients, plasma adiponectin concentration is almost three times higher than in healthy subjects [40,65]. However, it remains unknown which fraction of adiponectin, i.e. globular or full-length protein, HMW, MMW or LMW adiponectin, mainly accumulates in subjects with impaired kidney function.

The increased plasma adiponectin concentration in CKD patients cannot be explained by its over-secretion by adipose tissue. The adiponectin gene (ApM1) expression in adipocytes is even decreased in patients with advanced CKD [66]. The kidney is certainly the main organ participating in the biodegradation and elimination of adiponectin from circulation. Thus as expected, successful kidney transplantation is accompanied by a prompt reduction, but not normalization, of plasma adiponectin concentration [67]. Moreover, measurement of plasma adiponectin concentration in the renal veins and aorta of patients with haemodynamically significant renal artery stenosis (>70%) further supports the kidney's role in the elimination of adiponectin from circulation [60].

Lower adiponectin gene expression in CKD patients may be partially explained by the micro-inflammation, frequently present in these patients. In the general population [68,69], as well as in haemodialysis patients [65,70], an inverse relationship was found between plasma concentrations of adiponectin and C-reactive protein (CRP). This clinical observation was confirmed by experimental studies indicating that TNF{alpha} and IL-6 inhibit adiponectin gene expression in cultured adipocytes [8,71,72].

Expression of receptors for adiponectin in CKD patients has not yet been studied. Therefore, it is not possible to exclude the notion that reduction of adiponectin receptors expression in CKD patients, followed by decreased tissue adiponectin sensitivity, remains similar to other states of low adiponectin gene expression, i.e. obesity and diabetes mellitus type 2.



   Plasma adiponectin concentration and cardiovascular morbidity in patients with CKD
Top
 Introduction
 Adiponectin--a unique adipokine...
 Adiponectin in chronic kidney...
 Plasma adiponectin concentration...
How to increase plasma...
 References
 
In the pioneer and seminal study by Zoccali et al. [40], low plasma adiponectin concentration was recognized as a new risk factor for cardiovascular morbidity. They studied 227 haemodialysis patients without heart failure. During the mean follow-up period of 31 months, 95 fatal or non-fatal cardiovascular events occurred. Plasma adiponectin concentration in patients with cardiovascular events was significantly lower than in event-free patients (13.7 vs 15.8 µg/ml) [40].

Recently, Maeda et al. [73] found, in a small cohort of haemodialysis patients, a significant negative relationship between plasma adiponectin concentration and left ventricular mass and a significant positive relationship between plasma adiponectin concentration and diastolic function index (E/A mitral valve). It seems that low plasma adiponectin concentration is a new risk factor for left ventricular hypertrophy and diastolic dysfunction in haemodialysis patients [73]. However, in kidney transplant patients, such a relationship between plasma adiponectin concentration and left ventricular mass was not found [74].

The observation of Zoccali et al. [40] was further confirmed by Becker et al. [61], in a group (n = 227) of patients with mild or moderate non-diabetic CKD (measured GFR between 38 and 96 ml/min). They found that CKD patients with a history of cardiovascular events are characterized by significantly lower plasma adiponectin concentration, in comparison with those without cardiovascular complications (4.1 vs 6.4 µg/ml). Subsequently, they followed-up a cohort of such patients for 54 months. In 10 patients, cardiovascular events occurred. Plasma adiponectin concentration in patients with cardiovascular events during this follow-up period was significantly lower (P < 0.01) than in event-free patients (3.0 vs 6.5 µg/ml) [61].

Recently, Iwashima et al. [75] studied 150 CKD patients. During the mean follow-up period of 32 months, 31 cardiovascular events (myocardial infarction, angina pectoris, stroke and transient ischaemic attack) occurred. Sex-specific median values of plasma adiponectin concentration were used to separate the higher from the lower plasma adiponectin group (for males 4.39; for females 6.84 µg/ml). Kaplan–Meier curves showed significantly lower event-free survival rate in the lower adiponectin group, when compared with the higher adiponectin group. In Cox analysis, each 1 µg/ml increase of adiponectin plasma concentration was associated with a 14% decrease the risk of cardiovascular events [75].

Studies by Becker et al. [61], Iwashima et al. [75] and Zoccali et al. [40] have shown that in CKD patients, relatively low plasma adiponectin concentration is associated with worsened cardiovascular outcome.

Menon et al. [76] estimated plasma adiponectin concentration in frozen samples, withdrawn from CKD patients in stages 3 and 4 participating in the MDRD study. In this study, 820 patients with wide GFR range (between 13 and 55 ml/min) were observed during a 10 year follow-up period. A total of 201 (25%) participants died of any cause, and 122 (15%) from cardiovascular disease. Kaplan–Meier curves did not show any significant associations between tertiles of plasma adiponectin concentration and all-cause mortality. In multivariable adjusted Cox models, each 1 µg/ml increase in adiponectin plasma concentration was unexpectedly associated with a 3% increase of risk for all-cause and 6% increased risk for cardiovascular mortality. These results may suggest that high, rather than low, plasma adiponectin concentration is associated with increased mortality in patients with CKD stages 3–4. This observation can be explained only by a strong relationship between GFR and plasma concentration of adiponectin. Menon et al. [76] have demonstrated that patients with the highest plasma adiponectin concentration tertile were characterized by a significantly lower GFR. It is well-known that impaired kidney function is a strong risk factor of all-cause and cardiovascular mortality [77,78]. Therefore, the wide range of GFR values in this study makes the results concerning the relationship between plasma adiponectin concentration and survival difficult to interpret.



   How to increase plasma adiponectin concentration?
Top
 Introduction
 Adiponectin--a unique adipokine...
 Adiponectin in chronic kidney...
 Plasma adiponectin concentration...
 How to increase plasma...
References
 
Taking into consideration all the aforementioned results from clinical trials, it seems that adiponectinaemia can be now recognized as a new, potentially modified, non-traditional cardiovascular risk factor. The introduction of strategies increasing plasma adiponectin concentration may be a promising new concept for the prevention of cardiovascular diseases in hypertensive or CKD patients and perhaps also in the general population.

Weight reduction in obese subjects, by gastric reduction surgery [79], lifestyle modifications [80] or medical therapy [81], was accompanied by an increased plasma adiponectin concentration. Similarly, treatment with thiazolidinediones strongly increases plasma adiponectin concentrations [82–86]. It is of interest that these two interventions, i.e. weight reduction and treatment with thiazolidinediones, particularly increase plasma concentration of insulin-sensitizing HMW adiponectin form [86–88]. Other drugs which increase to a certain extent plasma adiponectin concentration are: angiotensin-converting enzyme inhibitors (temocapril and ramipril) [89,90], angiotensin II receptor 1 blockers (losartan, candesartan, valsartan and telmisartan) [89,91–94], clonidine-like sympatoinhibitory antihypertensive agent (rilmenidine) [95], fenofibrate [96] and cannabinoid-1 receptor blocker (rimonabant) [97]. This might provide a scientific rationale for a more frequent use of these drugs, in order also to increase plasma adiponectin concentration in high risk populations. In contrast to the aforementioned drugs, therapy with indapamide (thiazide-like diuretic) does lead to the reduction of plasma adiponectin concentration in patients with essential hypertension [98]. The importance of this observation for clinical outcome remains to be elucidated.

The majority of the strategies, described earlier in this article, aimed at increasing plasma adiponectin concentration, were studied only in patients with normal renal function. Only two studies were performed in different groups of CKD patients [99,100]. Yenicesu et al. [99] showed that in patients with type 2 diabetes mellitus and proteinuria but normal plasma creatinine, concentration treatment with ramipril was accompanied by an increased plasma adiponectin concentration. Furuya et al. [100] observed that plasma adiponectin concentration was higher in peritoneal dialysis patients after candesartan therapy.

However, it should be stressed that up to now, there is no single interventional study evaluating the potential effect of increased plasma adiponectin concentration on cardiovascular morbidity and mortality. Therefore, the effectiveness of cardiovascular risk reduction by increasing plasma adiponectin concentration should be a matter for future studies in the general population, hypertensive or CKD patients.

Conflict of interest statement. None declared.



   References
Top
 Introduction
 Adiponectin--a unique adipokine...
 Adiponectin in chronic kidney...
 Plasma adiponectin concentration...
 How to increase plasma...
 References
 

  1. Chudek J, Adamczak M, Nieszporek T, Wiecek A. (2006) The adipose tissue as an endocrine organ – a nephrologists’ perspective. Contrib Nephrol 151:70–90.[ISI][Medline]
  2. Wiecek A, Kokot F, Chudek J, Adamczak M. (2002) The adipose tissue – a novel endocrine organ of interest to the nephrologist. Nephrol Dial Transplant 17:191–195.[Free Full Text]
  3. Lihn AS, Pedersen SB, Richelsen B. (2005) Adiponectin: action, regulation and association to insulin sensitivity. Obes Rev 6:13–21.[CrossRef][ISI][Medline]
  4. Lihn AS, Bruun JM, He G, Pedersen SB, Jensen PF, Richelsen B. (2004) Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. Mol Cell Endocrinol 219:9–15.[CrossRef][ISI][Medline]
  5. Arita Y, Kihara S, Ouchi N, et al. (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79–83.[CrossRef][ISI][Medline]
  6. Peake PW, Kriketos AD, Denyer GS, Campbell LV, Charlesworth JA. (2003) The postprandial response of adiponectin to a high-fat meal in normal and insulin-resistant subjects. Int J Obes Relat Metab Disord 27:657–662.[CrossRef][ISI][Medline]
  7. Kadowaki T and Yamauchi T. (2005) Adiponectin and adiponectin receptors. Endocr Rev 26:439–451.[Abstract/Free Full Text]
  8. Wang B and Trayhurn P. (2006) Acute and prolonged effects of TNF-alpha on the expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture. Pflugers Arch 452:418–427.[CrossRef][ISI][Medline]
  9. Suganami T, Nishida J, Ogawa Y. (2005) A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler Thromb Vasc Biol 25:2062–2068.[Abstract/Free Full Text]
  10. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796–1808.[CrossRef][ISI][Medline]
  11. Fain JN, Bahouth SW, Madan AK. (2004) TNF alpha release by the nonfat cells of human adipose tissue. Int J Obes Relat Metab Disord 28:616–622.[CrossRef][ISI][Medline]
  12. Halleux CM, Takahashi M, Delporte ML, et al. (2001) Secretion and regulation of ApM 1 gene expression in human visceral adipose tissue. Biochem Biophys Res Commun 288:1102–1107.[CrossRef][ISI][Medline]
  13. Hotto K, Funahashi T, Arita Y, et al. (2000) Plasma concentration of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595–1599.[Abstract/Free Full Text]
  14. Iwashima Y, Katsuya T, Ishikawa K, et al. (2005) Association of hypoadiponectinemia with smoking habit in men. Hypertension 45:1094–1100.[Abstract/Free Full Text]
  15. Dzielinska Z, Januszewicz A, Wiecek A, et al. (2003) Decreased plasma concentration of a novel anti-inflammatory protein-adiponectin-in hypertensive men with coronary artery disease. Thromb Res 110:365–369.[CrossRef][ISI][Medline]
  16. Adamczak M, Wiecek A, Funahashi T, Chudek J, Kokot F, Matsuzawa Y. (2003) Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 16:72–75.[CrossRef][ISI][Medline]
  17. Yang W and Chuang L. (2006) Human genetics of adiponectin in the metabolic syndrome. J Mol Med 84:112–121.[CrossRef][ISI][Medline]
  18. Yamauchi T, Kamon J, Ito Y, et al. (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762–769.[CrossRef][Medline]
  19. Hattori Y, Suzuki M, Hattori K, Kasai K. (2003) Globular adiponectin upregulates nitric oxide production in vascular endothelial cells. Diabetologia 46:1543–1549.[CrossRef][ISI][Medline]
  20. Rasmussen MS, Lihn AS, Pedersen SB, Bruun JM, Rasmussen M, Richelsen B. (2006) Adiponectin receptors in human adipose tissue: effects of obesity, weight loss, and fat depots. Obesity 14:28–35.
  21. Debard C, Laville M, Berbe V, et al. (2004) Expression of key genes of fatty acid oxidation, including adiponectin receptors in skeletal muscle of type 2 diabetic patients. Diabetologia 47:917–925.[CrossRef][ISI][Medline]
  22. Kim MJ, Maachi M, Debard C, et al. (2006) Increased adiponectin receptor-1 expression in adipose tissue of impaired glucose-tolerant obese subjects during weight loss. Eur J Endocrinol 155:161–165.[Abstract/Free Full Text]
  23. Ouchi N, Kihara S, Arita Y, et al. (1999) Novel modulator for endothelial adhesion molecules adipocyte-derived plasma protein adiponectin. Circulation 100:2473–2476.
  24. Ouchi N, Kihara S, Arita Y, et al. (2001) Adipocyte – derived plasma protein, adiponectin, suppress lipid accumulation and class A receptor expression in human monocyte-derived macrophages. Circulation 103:1057–1063.
  25. Motoshima H, Wu X, Mahadev K, Goldstein BJ. (2004) Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem Biophys Res Commun 315:264–271.[CrossRef][ISI][Medline]
  26. Magalang UJ, Rajappan R, Hunter MG, et al. (2006) Adiponectin inhibits superoxide generation by human neutrophils. Antioxid Redox Signal 8:2179–2186.[CrossRef][ISI][Medline]
  27. Arita Y, Kihara S, Ouchi N, et al. (2002) Adipocyte-derived plasma protein, adiponectin, acts as a platelet–derived growth-factor-BB-binding protein and regulates growth factor-induced common post-receptor signal in vascular smooth muscle cell. Circulation 105:2893–2898.
  28. Wang Y, Lam KS, Xu JY, et al. (2005) Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J Biol Chem 280:18341–18347.[Abstract/Free Full Text]
  29. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. (2003) Adiponectin stimulates nitric oxide production in vascular endothelial cells. J Biol Chem 278:45021–45026.[Abstract/Free Full Text]
  30. Ouchi N, Ohishi M, Kihara S, et al. (2003) Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 42:231–234.[Abstract/Free Full Text]
  31. Okamoto Y, Kihara S, Ouchi N, et al. (2002) Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106:2767–2670.
  32. Yamauchi T, Kamon J, Waki H, et al. (2003) Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278:2461–2468.[Abstract/Free Full Text]
  33. Kumada M, Kihara S, Ouchi N, et al. (2004) Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 109:2046–2049.
  34. Shibata R, Sato K, Pimentel DR, et al. (2005) Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 11:1096–1103.[CrossRef][ISI][Medline]
  35. Shibata R, Ouchi N, Sato K, et al. (2006) Adiponectin regulates myocardial remodelling after myocardial infarction. J Hypertens 24:Suppl 6, 80.
  36. Shibata R, Ouchi N, Kihara S, Sato K, Funahashi T, Walsh K. (2004) Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of amp-activated protein kinase signaling. J Biol Chem 279:28670–28674.[Abstract/Free Full Text]
  37. Yang H, Zhang R, Mu H, Li M, Yao Q, Chen C. (2006) Adiponectin promotes endothelial cell differentiation from human peripheral CD14+ monocytes in vitro. J Cell Mol Med 10:459–469.[ISI][Medline]
  38. Liao Y, Takashima S, Maeda N, et al. (2005) Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc Res 67:705–713.[Abstract/Free Full Text]
  39. Shibata R, Ouchi N, Ito M, et al. (2004) Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 10:1384–1389.[CrossRef][ISI][Medline]
  40. Zoccali C, Mallamaci F, Tripepi G, et al. (2002) Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13:134–141.[Abstract/Free Full Text]
  41. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. (2004) Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 14:1730–1737.
  42. Schulze MB, Shai I, Rimm EB, Li T, Rifai N, Hu FB. (2005) Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 54:534–539.[Abstract/Free Full Text]
  43. Cavusoglu E, Ruwende C, Chopra V, et al. (2006) Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. Eur Eart J 27:2300–2309.
  44. von Eynatten M, Schneider JG, Humpert PM, et al. (2006) Serum adiponectin level are an independent predictor of the extent of coronary artery disease in men. J Am Coll Cardiol 46:2124–2126.
  45. Otsuka F, Sugiyama S, Kojima S, et al. (2006) Plasma adiponectin levels are associated with coronary lesion complexity in men with coronary artery disease. J Am Coll Cardiol 48:1155–1162.[Abstract/Free Full Text]
  46. Nilsson PM, Engstrom G, Hedblad B, et al. (2006) Plasma adiponectin levels in relation to carotid intima media thickness and markers of insulin resistance. Arterioscler Thromb Vasc Biol 26:2758–2762.[Abstract/Free Full Text]
  47. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. (2006) Adiponectin and adiponectin receptors in insulin resistance, diabetes, and metabolic syndrome. J Clin Invest 116:1784–1792.[CrossRef][ISI][Medline]
  48. Yamauchi T, Kamon J, Waki H, et al. (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941–946.[CrossRef][ISI][Medline]
  49. Ceddia RB, Somwar R, Maida A, Fang X, Bikopoulos G, Sweeney G. (2005) Globular adiponectin increases GLUT4 translocation and glucose uptake but reduces glycogen synthesis in rat skeletal muscle cells. Diabetologia 48:132–139.[CrossRef][ISI][Medline]
  50. Fu Y, Luo N, Klein RL, Garvey WT. (2005) Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation. J Lipid Res 46:1369–1379.[Abstract/Free Full Text]
  51. Hara K, Horikoshi M, Yamauchi T, et al. (2006) Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 29:1357–1362.[Abstract/Free Full Text]
  52. Waki H, Yamauchi T, Kamon J, et al. (2003) Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 278:40352–40363.[Abstract/Free Full Text]
  53. Hotta K, Funahashi T, Bodkin NL, et al. (2001) Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during progression to type 2 diabetes in rhesus monkeys. Diabetes 50:1126–1133.[Abstract/Free Full Text]
  54. Spranger J, Kroke A, Mohlig M, et al. (2003) Adiponectin and protection against type 2 diabetes mellitus. Lancet 361:226–228.[CrossRef][ISI][Medline]
  55. Snijder MB, Heine RJ, Seidell JC, et al. (2006) Associations of Adiponectin Levels With Incident Impaired Glucose Metabolism and Type 2 Diabetes in Older Men and Women: the Hoorn Study. Diabetes Care 29:2498–2503.[Abstract/Free Full Text]
  56. Bayes B, Lauzurica R, Granada ML, et al. (2004) Adiponectin and risk of new-onset diabetes mellitus after kidney transplantation. Transplantation 78:26–30.[ISI][Medline]
  57. Jaquet D, Deghmoun S, Chevenne D, Czernichow P, Lévy-Marchal C. (2006) Low serum adiponectin levels in subjects born small for gestational age: impact on insulin sensitivity. Int J Obes 30:83–87.[CrossRef][ISI][Medline]
  58. Adamczak M, Rzepka E, Chudek J, Wiecek A. (2005) Ageing and plasma adiponectin concentration in apparently healthy males and females. Clin Endocrinol 62:114–118.[CrossRef][Medline]
  59. Mallamaci F, Zoccali C, Cuzzola F, et al. (2002) Adiponectin in essential hypertension. J Nephrol 15:507–511.[ISI][Medline]
  60. Adamczak M, Czerwienska B, Chudek J, Wiecek A. Renal extraction of circulating adiponectin in patients with renovascular hypertension. Acta Physiol Hung (in press).
  61. Becker B, Kronenberg F, Kielstein JT, et al. (2005) Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol 16:1091–1098.[Abstract/Free Full Text]
  62. Saraheimo M, Forsblom C, Fagerudd J, et al. (2005) Serum adiponectin is increased in type 1 diabetic patients with nephropathy. Diabetes Care 28:1410–1414.[Abstract/Free Full Text]
  63. Schalkwijk CG, Chaturvedi N, Schram MT, Fuller JH, Stehouwer CD. EURODIAB Prospective Complications Study Group. (2006) Adiponectin is inversely associated with renal function in type 1 diabetic patients. J Clin Endocrinol Metab 91:129–135.[Abstract/Free Full Text]
  64. Adamczak M, Szotowska M, Chudek J, Karkoszka H, Cierpka L, Wiecek A. Plasma adiponectin concentration in patients after successful kidney transplantation – a single centre, observational study. Clinical Nephrology (submitted).
  65. Ignacy W, Chudek J, Adamczak M, et al. (2005) Reciprocal association of plasma adiponectin and serum C-reactive protein concentration in haemodialysis patients with end-stage kidney disease – a follow-up study. Nephron Clin Pract 101:c18–c24.[CrossRef][ISI][Medline]
  66. Marchlewska A, Stenvinkel P, Lindholm B, et al. (2004) Reduced gene expression of adiponectin in fat tissue from patients with end-stage renal disease. Kidney Int 66:46–50.[CrossRef][ISI][Medline]
  67. Chudek J, Adamczak M, Karkoszka H, et al. (2003) Plasma adiponectin concentration before and after successful kidney transplantation. Transplant Proc 35:2186–2189.[CrossRef][ISI][Medline]
  68. Ouchi N, Kihara S, Funahashi T, et al. (2003) Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 107:671–674.
  69. Engeli S, Feldpausch M, Gorzelniak K, et al. (2003) Association between adiponectin and mediators of inflammation in obese women. Diabetes 52:942–947.[Abstract/Free Full Text]
  70. Lee CT, Lee CH, Su Y, Chuang YC, Tsai TL, Cheni JB. (2004) The relationship between inflammatory markers, leptin and adiponectin in chronic hemodialysis patients. Int J Artif Organs 27:835–841.[ISI][Medline]
  71. Fasshauer M, Kralisch S, Klier M, et al. (2003) Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun 301:1045–1050.[CrossRef][ISI][Medline]
  72. Kappes A and Loffler G. (2000) Influences of ionomycin, dibutyryl-cycloAMP and tumour necrosis factor-alpha on intracellular amount and secretion of apM1 in differentiating primary human preadipocytes. Horm Metab Res 32:548–554.[ISI][Medline]
  73. Maeda T, Taniguchi S, Sasaki H, et al. (2006) Relationship between plasma adiponectin and cardiac function in patients with end-stage renal disease. J Hypertens 24:Suppl 6, 302.
  74. Adamczak M, Blach A, Kolonko A, et al. (2006) Does relationship exist between plasma adiponectin concentration and left ventricular mass in kidney transplant patients? Nephrol Dial Transplant 21:Suppl 4, iv276.
  75. Iwashima Y, Horio T, Suzuki Y, et al. (2006) Adiponectin and renal function, and risk of cardiovascular disease. J Hypertens 24:Suppl 6, 354.
  76. Menon V, Li L, Wang X, et al. (2006) Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol 16:1091–1098.
  77. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296–1305.[Abstract/Free Full Text]
  78. Sarnak MJ, Levey AS, Schoolwerth AC, et al. (2003) Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108:2154–2169.
  79. Yang WS, Lee WJ, Funahashi T, et al. (2001) Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 86:3815–3819.[Abstract/Free Full Text]
  80. Esposito K, Pontillo A, Di Palo C, et al. (2003) Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 289:1799–1804.[Abstract/Free Full Text]
  81. Valsamakis G, McTernan PG, Chetty R, et al. (2004) Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines. Metabolism 53:430–434.[CrossRef][ISI][Medline]
  82. Yu JG, Javorschi S, Hevener AL, et al. (2002) The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51:2968–2974.[Abstract/Free Full Text]
  83. Hirose H, Kaqwai T, Yamamoto Y, et al. (2002) Effects of pioglitasone on metabolic parameters, body fat distribution and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metab Clin Exp 51:314–317.
  84. Phillips SA, Ciaraldi TP, Kong AP, et al. (2003) Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes 52:667–674.[Abstract/Free Full Text]
  85. Yang WS, Jeng CY, Wu TJ, et al. (2002) Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 25:376–380.[Abstract/Free Full Text]
  86. Tonelli J, Li W, Kishore P, et al. (2004) Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. Diabetes 53:1621–1629.[Abstract/Free Full Text]
  87. Bobbert T, Rochlitz H, Wegewitz U, et al. (2005) Changes of adiponectin oligomer composition by moderate weight reduction. Diabetes 54:2712–2719.[Abstract/Free Full Text]
  88. Pajvani UB, Hawkins M, Combs TP, et al. (2004) Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 279:12152–12162.[Abstract/Free Full Text]
  89. Furuhashi M, Ura N, Higashiura K, et al. (2003) Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 42:76–82.[Abstract/Free Full Text]
  90. Koh K, Quon M, Han S, et al. (2005) Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension 45:1088–1093.[Abstract/Free Full Text]
  91. Koh K, Quon M, Han S, et al. (2004) Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 110:3687–3692.
  92. Koh K, Quon M, Han S, Chung WJ, Lee Y, Shin EK. (2005) Anti-inflammatory and metabolic effects of candesartan in hypertensive patients. Int J Cardiol 108:96–100.
  93. Shmieder R, Schlaich M, Mimran A, Fauvel JP, Ruilope LM. (2006) The cytokine adiponectin is disparately influenced by telmisartan and ramipril in type 2 diabetes. J Hypertens 24:Suppl 6, 225.
  94. Fogari R, Derosa G, Mugellini A, et al. (2006) Effect of valsartan and eprosartan on adiponectin, leptin and insulin sensitivity in hypertensive obese patients. J Hypertens 24:Suppl 6, 258.
  95. Nowak L, Adamczak M, Wiecek A. (2005) Blockade of sympathetic nervous system activity by rilmenidine increases plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 18:1470–1475.[CrossRef][ISI][Medline]
  96. Koh K, Quon M, Han S, et al. (2005) Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol 45:1649–1653.[Abstract/Free Full Text]
  97. Despres JP, Golay A, Sjostrom L. (2005) Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353:2121–2134.[Abstract/Free Full Text]
  98. Wiecek A, Piecha G, Chudek J, Adamczak M. (2006) Influence of different antihypertensive drugs on plasma adiponectin concentration in patients with essential hypertension. J Hypertens 24:Suppl 6, 356.
  99. Yenicesu M, Yilmaz MI, Caglar K, et al. (2005) Blockade of the renin-angiotensin system increases plasma adiponectin concentration in type 2 diabetic patients with proteinuria. Nephron Clin Pract 99:c115–c121.[CrossRef][ISI][Medline]
  100. Furuya R, Odamaki M, Kumagai H, Hishida A. (2006) Impact of angiotensin II receptor blocker on plasma levels of adiponectin and advanced oxidation protein products in peritoneal dialysis patients. Blood Purif 24:445–450.[CrossRef][Medline]
Received for publication: 20. 9.06
Accepted in revised form: 13.12.06


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in NDT:

In this issue ...

NDT 2007 22: i. [Extract] [FREE Full Text]  




This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
22/4/981    most recent
gfl814v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in NDT
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Wiecek, A.
Right arrow Articles by Chudek, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wiecek, A.
Right arrow Articles by Chudek, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?